TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

David R Spigel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.